Update on mupirocin resistance
- PMID: 8609541
Update on mupirocin resistance
Abstract
Mupirocin inhibits the activity of bacterial isoleucyl-tRNA synthetase resulting in a decrease or cessation of protein synthesis. Expression of resistance in staphylococci has been divided arbitrarily into two groups, low level (minimum inhibitory concentrations [MIC] of between 8 and 256 mg/L) and high level (MICs of > or = 512 mg/L). Low level resistance is associated with spontaneous mutational events, while high level resistance is mediated by a large transferable plasmid. The introduction of a nasal formulation of mupirocin raises many issues concerning staphylococcal breakpoints, since 20,000 mg/L is applied to the mucosal surface to eradicate nasal colonisation with staphylococci, as opposed to eliminating infection. For several years after its introduction reports of resistance in staphylococci were rare. However, the contemporary literature indicates reports of resistance in select populations, particularly associated with dermatology patients. The overall rate of resistance for organisms isolated from the nares is currently unknown. The recent introduction of the E test combined with the 5 microgram screening disk may assist in determining resistance rates in large populations.
Similar articles
-
Emergence and spread of low-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from a community hospital in Japan.J Hosp Infect. 2001 Apr;47(4):294-300. doi: 10.1053/jhin.2000.0931. J Hosp Infect. 2001. PMID: 11289773
-
Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001.Int J Antimicrob Agents. 2004 Jun;23(6):577-81. doi: 10.1016/j.ijantimicag.2003.11.007. Int J Antimicrob Agents. 2004. PMID: 15194128
-
Surveillance for mupirocin resistance following introduction of routine peri-operative prophylaxis with nasal mupirocin.J Hosp Infect. 2006 Mar;62(3):327-32. doi: 10.1016/j.jhin.2005.09.022. Epub 2005 Dec 27. J Hosp Infect. 2006. PMID: 16377029
-
Mupirocin resistance.Clin Infect Dis. 2009 Sep 15;49(6):935-41. doi: 10.1086/605495. Clin Infect Dis. 2009. PMID: 19673644 Review.
-
Exploring mechanisms of mupirocin resistance and hyper-resistance.Biochem Soc Trans. 2024 Jun 26;52(3):1109-1120. doi: 10.1042/BST20230581. Biochem Soc Trans. 2024. PMID: 38884776 Review.
Cited by
-
Interpretive criteria for testing susceptibility of staphylococci to mupirocin.Antimicrob Agents Chemother. 1997 May;41(5):1137-9. doi: 10.1128/AAC.41.5.1137. Antimicrob Agents Chemother. 1997. PMID: 9145883 Free PMC article.
-
Phenotypic and molecular characterization of Staphylococcus aureus isolates expressing low- and high-level mupirocin resistance in Nigeria and South Africa.BMC Infect Dis. 2009 Jan 28;9:10. doi: 10.1186/1471-2334-9-10. BMC Infect Dis. 2009. PMID: 19175912 Free PMC article.
-
Molecular detection of antimicrobial resistance.Clin Microbiol Rev. 2001 Oct;14(4):836-71, table of contents. doi: 10.1128/CMR.14.4.836-871.2001. Clin Microbiol Rev. 2001. PMID: 11585788 Free PMC article. Review.
-
Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci.Antimicrob Agents Chemother. 2006 Jul;50(7):2583-6. doi: 10.1128/AAC.01432-05. Antimicrob Agents Chemother. 2006. PMID: 16801451 Free PMC article.
-
Antibacterial activity of REP8839, a new antibiotic for topical use.Antimicrob Agents Chemother. 2005 Oct;49(10):4247-52. doi: 10.1128/AAC.49.10.4247-4252.2005. Antimicrob Agents Chemother. 2005. PMID: 16189105 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical